Comparison of spirometric markers of severity and reversibility in patients with asthma and/or COPD in NOVELTY
Rod Hughes, Ricardo Del Olmo, Barry Make, David Price, Alvar Agustí, Eleni Rapsomaniki, Hana Müllerová, Jørgen Vestbo
European Respiratory Journal 2020 56: 3759; DOI: 10.1183/13993003.congress-2020.3759
Rod Hughes
1AstraZeneca, Cambridge, United Kingdom
Ricardo Del Olmo
2Diagnostic and Treatment Department, Hospital de Rehabilitación Respiratoria "María Ferrer" and IDIM CR, Buenos Aires, Argentina
Barry Make
3National Jewish Health and University of Colorado Denver, Denver, CO, United States of America
David Price
4Observational and Pragmatic Research Institute, Singapore, and Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, United Kingdom
Alvar Agustí
5Respiratory Institute, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERES, Barcelona, Spain
Eleni Rapsomaniki
1AstraZeneca, Cambridge, United Kingdom
Hana Müllerová
1AstraZeneca, Cambridge, United Kingdom
Jørgen Vestbo
6University of Manchester and Manchester University NHS Foundation Trust, Manchester, United Kingdom
Vol 56 Issue suppl 64
Table of Contents
Comparison of spirometric markers of severity and reversibility in patients with asthma and/or COPD in NOVELTY
Rod Hughes, Ricardo Del Olmo, Barry Make, David Price, Alvar Agustí, Eleni Rapsomaniki, Hana Müllerová, Jørgen Vestbo
European Respiratory Journal Sep 2020, 56 (suppl 64) 3759; DOI: 10.1183/13993003.congress-2020.3759
Comparison of spirometric markers of severity and reversibility in patients with asthma and/or COPD in NOVELTY
Rod Hughes, Ricardo Del Olmo, Barry Make, David Price, Alvar Agustí, Eleni Rapsomaniki, Hana Müllerová, Jørgen Vestbo
European Respiratory Journal Sep 2020, 56 (suppl 64) 3759; DOI: 10.1183/13993003.congress-2020.3759